Utility of Trimethoprim-sulfamethoxazole Use in Skin Abscess Management

PHASE4CompletedINTERVENTIONAL
Enrollment

161

Participants

Timeline

Start Date

July 31, 2006

Primary Completion Date

February 29, 2008

Study Completion Date

May 31, 2008

Conditions
Skin Diseases, Infectious
Interventions
DRUG

Trimethoprim-sulfamethoxazole

Participants were randomized to receive placebo or trimethoprim/sulfamethoxazole using a computer randomization program on the initial presentation. The placebo is a Maalox and tonic water combination that resembled the antibiotic in color, texture and taste. The antibiotic dose is a standard trimethoprim/sulfamethoxazole for bacterial infection (10-12mg trimethoprim/kg/day, with a maximum adult dose of 160mg trimethoprim/day, divided into two doses). The concentration of the liquid is 200mg sulfamethoxazole/40mg trimethoprim per 5mL. With a maximum dose of 160mg trimethoprim, this equates to 20mL.

DRUG

Placebo group

Placebo (Maalox with simethicone and bitter mixture) suspension was dispensed to study participants who were block randomized to receive the placebo.

Trial Locations (1)

63104

Cardinal Glennon Children's Medical Center, St Louis

All Listed Sponsors
lead

St. Louis University

OTHER

NCT00679302 - Utility of Trimethoprim-sulfamethoxazole Use in Skin Abscess Management | Biotech Hunter | Biotech Hunter